Interventional procedure overview of transcatheter aortic valve implantation for native aortic valve regurgitation
Closed for comments This consultation ended on at Request commenting lead permission
Existing assessments of this procedure
The European Society of Cardiology guidelines (ESC/EACTS 2022) state that "TAVI may be considered in experienced centers for selected patients with AR and ineligible for SAVR" (Vahanian 2022).
The American College of Cardiology/American Heart/Association clinical practice guideline (ACC/AHA 2020), recommends that "in patients with isolated severe AR who have indications for SAVR and are candidates for surgery, TAVI should not be performed".
"TAVI for isolated chronic AR is challenging because of dilation of the aortic annulus and aortic root and, in many patients, lack of sufficient leaflet calcification. Risks of TAVI for treatment of AR include transcatheter valve migration and significant paravalvular leak. TAVI is rarely feasible, and then only in carefully selected patients with severe AR and HF who have a prohibitive surgical risk and in whom valvular calcification and annular size are appropriate for a transcatheter approach" (Oto 2021).
How are you taking part in this consultation?
You will not be able to change how you comment later.
You must be signed in to answer questions